Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 18;30(1):9–19. doi: 10.1093/ibd/izad126

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Changes in alpha and beta diversity and taxonomy in responders during the 4 weeks of corticosteroid therapy. A, Alpha diversity showed no significant changes in samples of responders at V1 compared with V2 determined by species richness, Shannon entropy and phylogenetic diversity (Kruskal Wallis: P > .05; V1 n = 69; V2 n = 63). B, Beta diversity showed a significant qualitative (Unweighted UniFrac) phylogenetic difference in the microbial composition of responders at V1 compared with V2 (PERMANOVA: P < .05; V1 n = 69; V2 n = 63). C, D, LEfSe analysis showed 23 significantly discriminative features in responders comparing microbial taxonomy in fecal samples at V1 and V2 with relative abundance (Logarithmic LDA score ≥4.0; P < .05; V1 n = 69; V2 n = 63). Dark green: baseline (V1), light green: after 4 weeks of corticosteroid therapy (V2). Abbreviation: NS, not significant. *P ≤ .05; **P ≤ .01.